B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma

• Amber Loren O. King, BA,
• Fatima N. Mirza, MPH,
• Julia M. Lewis, PhD,
• Kacie R. Carlson, PA,
• Scott Huntington, MD, MPH,
• Francine M. Foss, MD,
• Michael Girardi, MD

Affiliations

Amber Loren O. King, BA

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut

Fatima N. Mirza, MPH

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut

Julia M. Lewis, PhD

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut

Kacie R. Carlson, PA

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut

Scott Huntington, MD, MPH

Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut

Francine M. Foss, MD

Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut

Michael Girardi, MD

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut; Correspondence to: Michael Girardi, MD, 333 Cedar Street, PO Box 208059, Department of Dermatology, Yale School of Medicine, New Haven, CT 06520.